Capricor Faces Securities Lawsuit Over BLA SAP Changes and FDA Process
Sep 1, 2026, 2:17 PM EDT1 sourcesAI-analyzed
Why it may matterVerify against the original reporting
Legal actions targeting misstatements around FDA processes can pressure biotech stocks due to potential settlements, increased scrutiny, and impact on milestone timelines. The prior 64% intraday drop demonstrates substantial downside sensitivity to litigation-type news in CAPR. Historically, biotech lawsuits surrounding regulatory approvals can erode valuation and cap upside until clarity from courts or settlements emerge.
AI summary
What happened, with direct paths to the underlying reporting
Kaplan Fox & Kilsheimer filed a securities class action against Capricor, alleging misstatements around the resubmitted Dermamiocel BLA and changes to the SAP that were not reviewed by the FDA before submission. Capricor’s shares dropped 64% to $7 on July 27, 2026, underscoring near-term risk to the program and potential liability if claims prove material. Lead-plaintiff deadlines loom September 28, 2026.
Capricor faces securities class action over BLA SAP changes. Allegations reference July 27 briefing.
CAPR stock fell 64% to $7 on July 27, 2026.
Class Period: Dec 17, 2025–Jul 26, 2026; lead plaintiff deadline Sept 28, 2026.
Allegations say final SAP version wasn't submitted to FDA before BLA submission.
Kaplan Fox & Kilsheimer is counsel; cites large prior recoveries in securities cases.
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.
Related signals
More source-backed signals connected by company or event
Capricor reported that the FDA extended the PDUFA target date for Deramiocel to November 22, 2026 after submitting a major amendment with 24-month HOPE-3 data aimed at a refined u…
Capricor Therapeutics surged in premarket trading after news the FDA is willing to review new data on its experimental Duchenne muscular dystrophy therapy. The regulatory openness…
Capricor reported that the FDA advisory committee found Deramiocel's evidence insufficient for Duchenne cardiomyopathy, a non-binding result that tempers near-term approval prospe…
Capricor Therapeutics faces a securities-law investigation by Johnson Fistel amid Reuters detailing FDA concerns over deramiocel data and trial design. The disclosure triggered a…
